• info@platform-residras.com

International Registry of Dravet Syndrome and other Syndromes correlated with genes on SCN1A and PCDH19

Zogenix: successo candidato ZX008 contro forma rara di epilessia In uno studio di fase avanzata, il candidato ZX008 di Zogenix per il trattamento con sindrome di Dravet, una rara forma di epilessia
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared a link.
GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol)... Approval for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome, two rare, severe childhood-onset epilepsies
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared a link.
Prossima l'approvazione FDA del primo farmaco derivato dalla cannabis La prossima settimana la FDA potrebbe approvare il primo farmaco derivato dalla cannabis. Si tratta di un prodotto della britannica GW Pharmaceuticals che
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared a link.
ILAE - International League Against Epilepsy Read the June 2018 ILAE Newsletter: New Classification Translations | Young Epilepsy Section | Spotlight on Georgia | VIREPA Applications open | Journal News | Congress deadlines: http://p0.vresp.com/vhtuGW.
If you want to sign up to receive the monthly news via ...
Quartz Columbia University researchers made a major breakthrough in teaching kids with cerebral palsy how to walk better.
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared Quartz's video.
GW Pharmaceuticals e la società controllata americana Greenwich Biosciences annunciano la pubblicazione di uno studio... GW Pharmaceuticals e la società controllata americana Greenwich Biosciences annunciano la pubblicazione di uno studio di fase 3 relativo a soluzione orale di cannabidiolo nella terapia della sindrome di Lennox-Gastaut nelThe New England Journal of Medicine- Il primo studio con ...
Sudden Death In Dravet May Be Caused by Hyperthermia, SCN1A Defect A combination of high body temperature, seizures and SCN1A mutations could lead to sudden death in Dravet syndrome patients, according to a case report.
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared a link.
Zogenix, Inc. | Therapeutic Solutions for CNS Disorders and Rare Disease Zogenix is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
Pubblication around ...
Delaying epilepsy onset could reduce impact on development The case of a young boy with a rare genetic disorder over a decade ago has led to a multi-million Euro research project that is raising hopes of new approaches to childhood epilepsy.
Pubblication around Dravet Syndrome and Drug Resistant ...
Stoke's Dravet Syndrome Therapy Shows Promise in Mouse Study Read about a treatment approach that Stoke Therapeutics is developing for Dravet syndrome and other genetic disorders showing promise in mice.
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared a link.
Error - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/?cmd=historysearch&querykey=2
PubMed comprises more than 28 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Load More